Avecho Biotechnology (ASX:AVE) Cash-to-Debt : 21.70 (As of Jun. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Avecho Biotechnology Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Avecho Biotechnology's cash to debt ratio for the quarter that ended in Jun. 2024 was 21.70.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Avecho Biotechnology could pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for Avecho Biotechnology's Cash-to-Debt or its related term are showing as below:

ASX:AVE' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.97 Med: 74.07 Max: No Debt
Current: 21.7

During the past 13 years, Avecho Biotechnology's highest Cash to Debt Ratio was No Debt. The lowest was 5.97. And the median was 74.07.

ASX:AVE's Cash-to-Debt is ranked better than
64.76% of 1487 companies
in the Biotechnology industry
Industry Median: 6.4 vs ASX:AVE: 21.70

Avecho Biotechnology Cash-to-Debt Historical Data

The historical data trend for Avecho Biotechnology's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Avecho Biotechnology Cash-to-Debt Chart

Avecho Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

33.10

11.28

34.73

5.97

31.45

Avecho Biotechnology Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash-to-Debt	Get a 7-Day Free Trial															57.94	5.97	13.59	31.45	21.70

Competitive Comparison of Avecho Biotechnology's Cash-to-Debt

For the Biotechnology subindustry, Avecho Biotechnology's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avecho Biotechnology's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Avecho Biotechnology's Cash-to-Debt falls into.

Avecho Biotechnology Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Avecho Biotechnology's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5.504	/	(0.077	+	0.098)
	=	31.45

Avecho Biotechnology's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4.838	/	(0.166	+	0.057)
	=	21.70

Avecho Biotechnology (ASX:AVE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Avecho Biotechnology Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Avecho Biotechnology's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Avecho Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avecho Biotechnology Ltd (ASX:AVE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

OEZ:Germany

Address

Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168

Website

https://www.avecho.com.au

Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skincare and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.

Avecho Biotechnology Headlines

No Headlines